CBIO
Crescent Biopharma, Inc.12.92
-0.29-2.2%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
216.83MP/E (TTM)
-Basic EPS (TTM)
-Dividend Yield
0%Recent Filings
10-K
FY2025 results
Crescent Biopharma posted FY2025 ended December 31, 2025 results reflecting its clinical-stage status with no revenue generated from product sales, consistent with ongoing losses typical for pre-commercial biotech. No quarterly financial breakdowns or Q4 metrics appear in the 10-K, so momentum indicators remain undisclosed. The company advanced key milestones, initiating the global Phase 1/2 ASCEND trial for CR-001 in Q1 2026 while planning CR-002 and CR-003 monotherapy trials in 2026. No debt, capex, or cash flow details provided. Clinical trial execution remains uncertain.
8-K
2025 results: loss, strong cash
Crescent Biopharma reported full-year 2025 net loss of $153.9 million, with R&D expenses surging to $138.1 million on CR-001 and CR-002 advances, offset by $10.8 million license revenue from Kelun-Biotech partnership. Cash hit $213.2 million post-$185 million private placement, funding into 2028. ASCEND trial dosed first patient.
8-K
Kelun deal, $185M PIPE
Crescent inked license swaps with Kelun-Biotech on Dec 2: granted CR-001 rights in Greater China for $20M upfront, up to $30M milestones, low-mid single-digit royalties; took ex-China SKB105 rights for $80M upfront, up to $1.25B milestones, mid-single to low-double-digit royalties. Paired with $185M private placement of 13.8M shares at $13.41, closing Dec 8, cash funds ops into 2028. Three programs hit clinic in 2026; data by 2027. Funded through readouts.
8-K
Q3 loss, strong cash, CR-001 IND
Crescent Biopharma reported Q3 2025 net loss of $24.6 million on $20.3 million R&D and $5.5 million G&A expenses, with cash at $133.3 million funding operations through 2027. CR-001 PD-1 x VEGF bispecific antibody stays on track for Q4 2025 IND and Q1 2026 Phase 1 start in solid tumors. Preclinical data impressed at SITC. Cash burn accelerates pipeline momentum.
10-Q
Q3 FY2025 results
Crescent Biopharma posted a $24.6M net loss for Q3 ended September 30, 2025, up from $2.6M in the prior-year stub period (derived), driven by ramped R&D on CR-001 ($8.7M external) and CR-002 ($6.7M). Cash swelled to $133.3M post-June reverse recap with GlycoMimetics (closed June 13 for $200M pre-closing financing, no goodwill recognized). Operating cash burn hit $44.8M YTD; no debt remains after convertible notes conversion. Preclinical-stage with no revenue. Reliance on Paragon for discovery heightens third-party risk.
IPO
Employees
Sector
Industry
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CLRB
Cellectar Biosciences, Inc.
3.18-0.02
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
CRBP
Corbus Pharmaceuticals Holdings
8.66-0.82
CRBU
Caribou Biosciences, Inc.
1.69-0.02
CUE
Cue Biopharma, Inc.
0.41-0.05
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MBIO
Mustang Bio, Inc.
1.07-0.06
XLO
Xilio Therapeutics, Inc.
0.65+0.00
YDES
YD Bio Limited
12.62+0.22